Cytokinetics (CYTK) Competitors

Cytokinetics logo
$53.17 -2.96 (-5.27%)
Closing price 04:00 PM Eastern
Extended Trading
$53.32 +0.16 (+0.29%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CYTK vs. ROIV, UTHR, INCY, INSM, and BNTX

Should you buy Cytokinetics stock or one of its competitors? Cytokinetics's main competitors and comparable companies include Roivant Sciences (ROIV), United Therapeutics (UTHR), Incyte (INCY), Insmed (INSM), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cytokinetics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Roivant Sciences presently has a consensus price target of $46.64, suggesting a potential upside of 17.98%. Cytokinetics has a consensus price target of $106.67, suggesting a potential upside of 90.04%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

In the previous week, Roivant Sciences had 16 more articles in the media than Cytokinetics. MarketBeat recorded 27 mentions for Roivant Sciences and 11 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.81 beat Roivant Sciences' score of 0.50 indicating that Cytokinetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

64.8% of Roivant Sciences shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cytokinetics has a net margin of -686.63% compared to Roivant Sciences' net margin of -838.21%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-838.21% -22.03% -20.55%
Cytokinetics -686.63%N/A -48.26%

Roivant Sciences has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Roivant Sciences has higher earnings, but lower revenue than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$8.26M3,467.54-$299.77M-$0.63N/A
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A

Summary

Roivant Sciences beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, United Therapeutics had 18 more articles in the media than Cytokinetics. MarketBeat recorded 29 mentions for United Therapeutics and 11 mentions for Cytokinetics. United Therapeutics' average media sentiment score of 0.96 beat Cytokinetics' score of 0.81 indicating that United Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United Therapeutics
13 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

94.1% of United Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

United Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

United Therapeutics currently has a consensus price target of $676.40, indicating a potential upside of 14.42%. Cytokinetics has a consensus price target of $106.67, indicating a potential upside of 90.04%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

United Therapeutics has a net margin of 38.61% compared to Cytokinetics' net margin of -686.63%. United Therapeutics' return on equity of 19.18% beat Cytokinetics' return on equity.

Company Net Margins Return on Equity Return on Assets
United Therapeutics38.61% 19.18% 17.07%
Cytokinetics -686.63%N/A -48.26%

United Therapeutics has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$3.18B7.91$1.33B$26.5022.31
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A

Summary

United Therapeutics beats Cytokinetics on 12 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Incyte?

Cytokinetics (NASDAQ:CYTK) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Incyte has a net margin of 6.71% compared to Cytokinetics' net margin of -686.63%. Incyte's return on equity of 7.92% beat Cytokinetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytokinetics-686.63% N/A -48.26%
Incyte 6.71%7.92%6.12%

Cytokinetics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Incyte has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

97.0% of Incyte shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Incyte had 7 more articles in the media than Cytokinetics. MarketBeat recorded 18 mentions for Incyte and 11 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.81 beat Incyte's score of 0.45 indicating that Cytokinetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytokinetics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Incyte
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral

Incyte has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A
Incyte$6.01B4.10$1.29B$1.8864.35

Cytokinetics currently has a consensus price target of $106.67, suggesting a potential upside of 90.04%. Incyte has a consensus price target of $132.86, suggesting a potential upside of 9.83%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44

Summary

Incyte beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Insmed?

Insmed (NASDAQ:INSM) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Insmed has a net margin of -39.85% compared to Cytokinetics' net margin of -686.63%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-39.85% -96.38% -32.55%
Cytokinetics -686.63%N/A -48.26%

Insmed presently has a consensus price target of $196.52, suggesting a potential upside of 62.20%. Cytokinetics has a consensus price target of $106.67, suggesting a potential upside of 90.04%. Given Cytokinetics' higher possible upside, analysts plainly believe Cytokinetics is more favorable than Insmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Cytokinetics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42M43.83-$1.28B-$2.82N/A
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A

In the previous week, Cytokinetics had 3 more articles in the media than Insmed. MarketBeat recorded 11 mentions for Cytokinetics and 8 mentions for Insmed. Insmed's average media sentiment score of 1.17 beat Cytokinetics' score of 0.81 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Insmed beats Cytokinetics on 9 of the 15 factors compared between the two stocks.

How does Cytokinetics compare to BioNTech?

Cytokinetics (NASDAQ:CYTK) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Cytokinetics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A
BioNTech$2.42B8.94-$1.29B-$6.85N/A

BioNTech has a net margin of -61.39% compared to Cytokinetics' net margin of -686.63%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Cytokinetics-686.63% N/A -48.26%
BioNTech -61.39%-4.51%-3.96%

Cytokinetics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cytokinetics currently has a consensus target price of $106.67, indicating a potential upside of 90.04%. BioNTech has a consensus target price of $122.27, indicating a potential upside of 42.83%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cytokinetics is more favorable than BioNTech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86
BioNTech
1 Sell rating(s)
5 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.68

In the previous week, Cytokinetics had 2 more articles in the media than BioNTech. MarketBeat recorded 11 mentions for Cytokinetics and 9 mentions for BioNTech. Cytokinetics' average media sentiment score of 0.81 beat BioNTech's score of 0.38 indicating that Cytokinetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytokinetics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Cytokinetics beats BioNTech on 10 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTK vs. The Competition

MetricCytokineticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.41B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-8.8024.2434.3430.11
Price / Sales65.3814.858.005.33
Price / CashN/A21.8921.0222.34
Price / Book-9.864.354.763.85
Net Income-$784.96M-$24.19M$3.52B$393.14M
7 Day Performance-3.57%-7.26%-5.34%-4.53%
1 Month Performance-14.17%-4.96%-3.61%-5.86%
1 Year Performance-19.97%-2.87%0.01%-7.78%

Cytokinetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYTK
Cytokinetics
3.0825 of 5 stars
$53.17
-5.3%
$106.67
+100.6%
-15.5%$7.82B$88.04MN/A673
ROIV
Roivant Sciences
2.3039 of 5 stars
$40.67
+4.6%
$46.55
+14.4%
+94.8%$27.61B$8.26MN/A721
UTHR
United Therapeutics
4.6582 of 5 stars
$582.46
+3.6%
$676.40
+16.1%
+26.8%$26.10B$3.18B21.981,400
INCY
Incyte
2.9477 of 5 stars
$121.89
+1.9%
$132.86
+9.0%
+16.1%$25.04B$5.14B57.952,844
INSM
Insmed
3.3329 of 5 stars
$116.10
+1.5%
$196.52
+69.3%
-37.3%$24.13B$606.42MN/A1,664

Related Companies and Tools


This page (NASDAQ:CYTK) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners